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INTRODUCTION
The need for kidney transplant continues to greatly exceed 
the available organ supply, as over 90 000 US residents 
are currently waiting for an organ.1 Consequently, every 
year thousands of patients die or are removed from the 
transplant waiting list before being offered an organ. At 
the same time, the rate of discard of potentially transplant-
able kidney allografts remains substantial.2 Active donor 
infection with hepatitis C virus (dHCV+), defined as evi-
dence of active viral replication by nucleic acid testing, 
Kidney Transplantation
Background. Kidney transplantation with hepatitis C viremic (dHCV+) donors appears safe for recipients without HCV 
when accompanied by direct acting antiviral (DAA) treatment. However, US programs have been reluctant to embrace this 
approach due to concern about insurance coverage. While the cost of DAA treatment is currently offset by the reduction 
in waiting time, increased competition for dHCV+ organs may reduce this advantage. This analysis sought to demonstrate 
the financial benefit of dHCV+ transplant for third-party health insurers to expand coverage availability. Methods. An 
economic analysis was developed using a Markov model for 2 decisions: first, to accept a dHCV+ organ versus wait for a 
dHCV uninfected organ; or second, accept a high kidney donor profile index (KDPI) (>85) organ versus wait for a better qual-
ity dHCV+ organ. The analysis used Medicare payments, historical survival data, cost report data, and an estimated cost of 
DAA of $29 874. Results. In the first analysis, using dHCV+ kidneys reduced the cost of end-stage kidney disease care 
if the wait for a dHCV uninfected organ exceeded 11.5 months. The financial breakeven point differed according to the cost 
of DAA treatment. In the second analysis, declining a high-KDPI organ in favor of a waiting dHCV+ organ was marginally 
clinically beneficial if waiting times were <12 months but not cost effective. Conclusions. dHCV+ transplant appears to 
be economically and clinically advantageous compared with waiting for dHCV-uninfected transplant but should not replace 
high-KDPI transplant when appropriate. Despite the high cost of DAA therapy, health insurers benefit financially from dHCV+ 
transplant within 1 year.
(Transplantation Direct 2020;6: e627; doi: 10.1097/TXD.0000000000001056. Published online 10 November, 2020.)
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has historically increased the risk of kidney nonutiliza-
tion.3 While use of dHCV+ organs in patients with active 
HCV has increased, the population of potentially accept-
able HCV-infected recipients remains small, limiting use 
of these organs if only infected patients are transplanted.
The landscape of HCV treatment changed in 2014 with 
the introduction of the first effective direct acting antiviral 
agents (DAAs), although the need for ribavirin limited their 
use in patients with renal dysfunction.4 DAA treatment of 
HCV has been shown to be highly effective in achieving a 
sustained viral response (SVR), defined as no detectable virus 
at 12 weeks. Recently, new regimens have been developed 
that overcome early limitations, allowing treatment all HCV 
genotypes in patients with kidney failure and after transplant. 
In this context, 2 landmark trials demonstrated that dHCV+ 
kidneys can be safely used in HCV-uninfected patients who 
are treated with DAAs shortly after transplant.5,6 Patients 
transplanted under these protocols waited <2 months for 
transplant, compared with 4–7 years for patients waiting for 
non-HCV infected organs. While clinically beneficial, broader 
use of these protocols had been limited by cost, as early 
commercially available DAA regimens exceeded $80 000.7 
Fortunately, competition has reduced the price of treatment 
substantially. Despite this reduction in cost, transplant pro-
grams remain reluctant to expand use of these organs due to 
concern about insurance coverage.7
To facilitate broad adoption of dHCV+ organ utilization, 
transplant centers need assurance that third-party health 
insurers will provide coverage for necessary DAAs. However, 
from a financial perspective, private insurance carriers do 
not bear the costs of life-long renal replacement therapy 
nor benefit from expansion of organ supply associated with 
the use of these organs. Therefore, the incremental cost of 
DAAs to clear HCV infection acquired from dHCV+ organs 
needs to be offset by a sufficient reduction dialysis time. 
The economic breakeven point needed is a function of the 
cost of DAA therapy, which is rapidly declining as shorter 
courses of treatment are demonstrated to be effective. To 
better understand the financial implications of using dHCV+ 
kidney transplant in HCV-uninfected recipients, we sought 
to estimate the minimal waiting time reduction required to 
justify acceptance of dHCV+ organs over a range of DAA 
treatment prices.
MATERIALS AND METHODS
Data Sources and Approval
This study used data from the US Renal Data System, 
the Scientific Registry of Transplant Recipients (SRTR), and 
transplant hospital Medicare Costs Reports (Table  1). The 
US Renal Data System database includes payment data for 
all patients on maintenance renal replacement therapy with 
Medicare as their primary insurance, including professional 
charges and payments for hospitalizations. The SRTR sys-
tem includes data on all donors, waitlisted candidates, and 
transplant recipients in the United States, submitted by the 
members of the Organ Procurement and Transplantation 
Network. The Health Resources and Services Administration, 
US Department of Health and Human Services, provides 
oversight of the activities of the Organ Procurement and 
Transplantation Network and SRTR contractors. National 
Medicare Cost Report data were obtained under a Freedom 
of Information Act request. This study was approved by the 
Saint Louis University Institutional Review Board.
This analysis was conducted from the health insurer 
(Medicare) perspective using methods described in previous 
publications.8 Medicare claims for 18 037 kidney transplant 
procedures performed from 2014 to 2016 were reviewed. 
Payments for technical services (part A) and professional ser-
vices/immunosuppression (part B) were aggregated for 3 cat-
egories of costs that relate to distinct periods:
• First, the cost of maintaining a patient on the kidney 
transplant waiting list (pretransplant) including the cost 
of hemodialysis for patients not listed preemptively. 
Medicare payments were aggregated for patients who 
were listed on the national US waiting list to determine 
an average monthly cost.
• Second, the cost of the transplant episode including the 
transplant and initial postoperative care was determined 
as the mean payment (parts A and B). In addition, mean 
national payment per kidney via the Medicare cost report 
was included based on data from 154 transplant centers 
obtained via a freedom of information act request (full 
data not shown). For patients who receive DAA treatment 
for HCV infection, the cost of medication, physician visits, 
and laboratory tests were included during this period.
• Third, posttransplant cost for technical services (part 
A) and professional services/ immunosuppression (part 
TABLE 1.




Dialysis Cost per mo of dialysis $4753 Medicare (part A/B)
 Waitlist mortality (age 48) 0.41% SRTR
 Waitlist mortality (age 65) 0.67% SRTR
KDPI=20-85 Cost of transplant $29 765 Medicare (part A/B)
KDPI=20-85 Cost report payment $68 567 Medicare cost report
KDPI=20-85 Total cost of transplant $98 332  
KDPI=20-85 Annual cost after transplant (first yr) $34 292 Medicare (part A/B)
KDPI=20-85 Annual cost after transplant 13–24 mo $14 049 Medicare (part A/B)
KDPI=20-85 Graft failure rate (pts/mo) 0.170% SRTR annual report
KDPI=20-85 Death rate (pts/mo) 0.190% SRTR annual report
KDPI> 85 Cost of transplant $31 557 Medicare (part A/B)
KDPI> 85 Cost report payment $68 567 Medicare cost report
KDPI> 85 Total cost of transplant $100 124  
KDPI> 85 Annual cost after transplant (first yr) $43 316 Medicare (part A/B)
KDPI> 85 Annual cost after transplant 13–24 mo $19 340 Medicare (part A/B)
KDPI> 85 Graft failure rate (pts/mo) 0.3% SRTR annual report
KDPI> 85 Death rate (pts/mo) 0.3% SRTR annual report
dHCV+ Cost of transplant $33 332 Medicare (part A/B)
dHCV+ Cost report payment $68 567 Medicare cost report
dHCV+ Cost of DAA (Mavyret) $27 610 Average wholesale 
price
dHCV+ Cost of labs (PCR X6, LFTs X4) $2265 Medicare (part A/B)
dHCV+ Total cost of transplant $131 733  
dHCV+ Annual cost after transplant (first yr) $34 292 Medicare (part A/B)
dHCV+ Annual cost after transplant 13–24 mo $14 049 Medicare (part A/B)
dHCV+ Graft failure rate (pts/mo) 0.150% SRTR annual report
dHCV+ Death rate (pts/mo) 0.150% SRTR annual report
DAA, direct acting antiviral; KDPI, kidney donor profile index; LFTs, liver function tests; SRTR, 
Scientific Registry of Transplant Recipients.
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B) were aggregated. Posttransplant cost did not include 
medication coverage under part D.
• The cost of graft failure and patient death were derived 
from Medicare payments for the month of the graft loss.
The basecase cost of DAA therapy was calculated from 
clinical trial protocols and Medicare allowable payments. The 
basecase included a 12-week course of glecaprevir/pibrentas-
vir, which has an average wholesale price of $9203 per 4-week 
course (Micromedex Redbook, Accessed February 17, 2020), 
3 visits to a hepatologist including liver function tests ($240 
per visit), and HCV PCR tests at week 0, 2, 4, 8, 12, and 24 
($257 per test). Total cost of basecase DAA treatment was 
$29 875. Sensitivity analyses examined costs from $5000 to 
$65 000 per treatment course.
Mortality rates for patients on the transplant waiting list 
and patient and graft survival after transplant were derived 
from transplant registry (SRTR) data based on kidney donor 
profile index (KDPI) for high- (>85) and lower-KDPI (≤85) 
organs, as reported in the SRTR annual report. Because 
patients who consent for high KDPI organs systematically dif-
fer from patients who do not consent to receive these organs, 
waitlist survival was modeled separately. For the lower KDPI 
analysis, waitlist survival was modeled for a 48-year-old 
patient; for the high KDPI analysis, waitlist mortality was 
modeled for a 65-year-old patient. Similarly, graft failure rates 
were derived from transplant registry analyses. Differences in 
patient and graft survival were calculated at 36 months after 
initial offer for this analysis.1
Analyses
A multistate Markov model was constructed including 
waitlist, transplanted, graft failure with return to dialysis, 
and death states. Transition probabilities were determined 
from published literature as summarized in Table 1. Patients 
can transition to death before transplant at rates based on 
the waitlisted population, after transplant with a functioning 
graft, or after graft failure. A 36-month model was constructed 
without discounting given the offsetting medical cost inflation 
and time value of money over this short period of analysis. A 
36-month analysis was chosen as this coincides with current 
Medicare payment policy for transplant and provides a rea-
sonable period for a health insurer to derive financial benefit.
Logically, patients offered a dHCV+ donor and dHCV-
uninfected donor at the same time with equal or better KDPI 
will choose the uninfected organ. Therefore, decision analytic 
models were constructed to compare cost and outcomes for 
2 scenarios. The first considered a waitlist patient offered the 
choice of accepting a dHCV+ organ (with DAA treatment) 
or waiting for a dHCV-uninfected organ of similar or better 
quality as defined by KDPI. For this analysis, we calculated 
the point of cost equivalence between accepting a dHCV+/
lower KDPI (≤85) kidney with waiting for a dHCV-uninfected 
organ of similar quality. The second scenario examined the 
choice of accepting a dHCV-uninfected/high KDPI kidney or 
waiting for a longer lasting lower-KDPI dHCV+ organ. This 
decision analysis reflects patients’ desire to wait for a lower 
KDPI kidney with the hope longer graft survival and the 
promise that a dHCV+ donor organ can be identified with 
only a short incremental waiting time.
Aggregated costs for kidney transplant were calculated for 
dHCV-uninfected/lower KDPI transplant, dHCV-uninfected/
high KDPI transplant, and dHCV+ transplant using the 
input data summarized in Table 1 to determine the time to 
cost equivalence. Patients with a graft failure were assumed 
to return to dialysis until the end of the period of analysis. 
Secondary analysis included patient survival and the cost-
effectiveness as determined by the cost per year of life saved 
to 36 months. Strategies which both increased life expectancy 
and lower spending were labeled as dominant. Sensitivity 
analyses examined the economic impact of varying the antici-
pated reduction in waiting time (between 0 and 30 mo) and 
the anticipated costs of DAA treatment.
RESULTS
In the base analysis, cost of dHCV+ kidney transplant 
($131 772) significantly exceeded the cost of dHCV-uninfected/
lower KDPI kidney transplant ($98 332) and dHCV-uninfected/
high KDPI transplant ($100 124). This cost reflects the need 
for DAA therapy ($29 874 per treatment). The cost of dialy-
sis for 36 months was $171 108. Three-year graft and patient 
survival were essentially equivalent for dHCV-uninfected (87% 
and 93%) and dHCV+ (89% and 95%) lower KDPI kidney 
transplant but were lower for dHCV-uninfected/high KDPI 
transplant recipients (77% and 88%). Survival on dialysis at 36 
months was 86.3% for lower-KDPI only consented candidates 
and 78.5% for high KDPI consented patients.
In the basecase analysis, the total cost of care over 36 
months was compared for patients who underwent transplant 
with a dHCV+/lower KDPI kidney and those who waited for a 
dHCV-uninfected organ. At 11.5 months, the cost of care was 
equivalent between the 2 strategies ($201 049 for immediate 
dHCV+ kidney transplant, $200 779 for a delayed dHCV-
uninfected kidney transplant). Accepting dHCV+ transplant 
resulted in improved 3-year expected survival (94.7%), com-
pared with waiting for a dHCV-uninfected organ (91.0%). 
Accepting a dHCV+ organ which reduced waiting times for 
transplant <11.5 months was associated with higher costs but 
greater survival compared with waiting for dHCV-uninfected 
transplant (Table  2). However, if a dHCV-uninfected organ 
was available in <6 months, dHCV+ was no longer cost effec-
tive (>$100 000 per life-year saved) over a 36-month analysis 
(Table  2). Sensitivity analysis confirmed that as the cost of 
DAA decreased, necessary waiting time reduction to achieve 
breakeven cost similarly decreased. For example, if the time 
to transplant with a dHCV− organ was only 6 months, the 
cost of DAA would need to decrease to <$15 000 to remain 
cost effective.
In the second analysis, accepting a dHCV-uninfected/high 
KDPI organ now was compared with waiting for a dHCV+/
lower KDPI organ. Over the 36 months, accepting a high KDPI 
organ was associated with lower total cost unless DAA treat-
ment was <$5000 even if offered simultaneously. Waiting for a 
dHCV+/lower KDPI organ for up to 12 months was associated 
with a small survival benefit at 36 months, while immediate 
acceptance KDPI organ is preferred for longer waiting peri-
ods. However, given the high incremental cost of DAA therapy, 
declining a dHCV-uninfected/high KDPI organ to wait for a 
dHCV/lower KDPI was not cost effective (Table 3).
DISCUSSION
Use of dHCV+ kidney transplant in recipients without 
HCV infection has been demonstrated to improve access to 
4 Transplantation DIRECT   ■   2020 www.transplantationdirect.com
kidney transplant, but the financial implications of this strat-
egy are not well defined. Based on this cost analysis of national 
US transplant registry and Medicare data, widespread use of 
dHCV+ kidney allografts appears justified if acceptance is 
associated with shorter waiting times to transplant. Given the 
current cost of DAA therapy, a reduction in waiting time of at 
least 11.5 months is necessary to demonstrate a cost savings. 
Waiting time reductions of at least 6 months were cost-effec-
tive at 36 months (based upon a threshold of $100 000 per 
life-year), with greater benefit possible as the period of analy-
sis is extended. This calculus is likely to change as demand 
for dHCV+ organs increases and the cost of DAA treatment 
decreases. In contrast, declining a high KDPI/dHCV− organ 
in hope of being offered a lower KDPI/dHCV+ kidney did 
not appear to be cost effective. As dHCV+ transplant is more 
costly and waitlist mortality is high, it is neither clinically 
advantageous nor financially sound over a short-time horizon 
to delay transplant if the high-KDPI kidney is otherwise 
appropriate.
In the Transplanting Hepatitis C Kidneys into Negative 
Kidney Recipients (THINKER) trial, Reese et al9 reported 
1-year outcomes of 10 uninfected patients who received 
dHCV+ kidneys followed by elbasvir–grazoprevir DAA ther-
apy at the onset of viremia, and 10 additional patients. All 
patients achieved SVR with excellent kidney function (mean 
creatinine 1.2 mg/dL) at 6 months without evidence of acute 
rejection. Patient-reported quality of life was excellent, with 
an improvement in the mean physical component summary 
on the RAND-36 scale 6.7 (P = 0.012) points from baseline. 
In the Exploring Renal Transplants Using Hepatitis C Infected 
Donors for HCV-negative Recipients (EXPANDER-1) trial, 
Durand et al6 described 10 uninfected patients who under-
went dHCV+ transplant with preemptive DAA treatment. All 
participants attained SVR at 12 weeks without evidence of 
TABLE 2.
Two-way sensitivity analysis showing the cost per year of life saved by accepting a dHCV+ kidney rather than waiting for 
a dHCV-uninfected kidney
 Anticipated reduction in waiting time
Cost of DAA 3 6 9 12 18 24 30
$5000 $100 038 dHCV+ DOM dHCV+ DOM dHCV+ DOM dHCV+ DOM dHCV+ DOM dHCV+ DOM
$10 000 $184 516 dHCV+ DOM dHCV+ DOM dHCV+ DOM dHCV+ DOM dHCV+ DOM dHCV+ DOM
$15 000 $268 994 $63 365 dHCV+ DOM dHCV+ DOM dHCV+ DOM dHCV+ DOM dHCV+ DOM
$20 000 $353 472 $127 840 dHCV+ DOM dHCV+ DOM dHCV+ DOM dHCV+ DOM dHCV+ DOM
$25 000 $437 950 $192 315 $41 202 dHCV+ DOM dHCV+ DOM dHCV+ DOM dHCV+ DOM
$30 000 $522 428 $256 791 $93 399 dHCV+ DOM dHCV+ DOM dHCV+ DOM dHCV+ DOM
$35 000 $606 906 $321 266 $145 596 $26 506 dHCV+ DOM dHCV+ DOM dHCV+ DOM
$40 000 $691 384 $385 741 $197 794 $70 400 dHCV+ DOM dHCV+ DOM dHCV+ DOM
$45 000 $775 862 $450 216 $249 991 $114 294 dHCV+ DOM dHCV+ DOM dHCV+ DOM
$50 000 $860 340 $514 691 $302 189 $158 188 dHCV+ DOM dHCV+ DOM dHCV+ DOM
$55 000 $944 818 $579 167 $354 386 $202 082 $8573 dHCV+ DOM dHCV+ DOM
$60 000 $1 029 296 $643 642 $406 583 $245 976 $41 953 dHCV+ DOM dHCV+ DOM
The cost of DAA therapy varies from $5000 to $60 000 and the time to first dHCV− kidney from 3 mo to 30 mo. The total period of analysis is 36 mo.
Green, cost effective; blue, survival improved but not cost effective; black, survival not improved despite higher cost.
DAA, direct acting antiviral; dHCV+, hepatitis C viremic donor kidney; DOM, dominant strategy with lower cost and improved survival. 
TABLE 3.
Two-way sensitivity analysis showing the cost per year of life saved by accepting a high KDPI kidney rather than waiting 
for a dHCV+/lower KDPI kidney
 Waiting time for low KDPI/dHCV+ kidney
Cost of DAA 3 6 9 12 18 24 30
$5000 $65 938 $203 216 $542 235 $2 686 885 High KDPI DOM High KDPI DOM High KDPI DOM
$10 000 $100 617 $252 873 $628 622 $3 004 685 High KDPI DOM High KDPI DOM High KDPI DOM
$15 000 $135 297 $302 530 $715 009 $3 322 485 High KDPI DOM High KDPI DOM High KDPI DOM
$20 000 $169 976 $352 188 $801 396 $3 640 285 High KDPI DOM High KDPI DOM High KDPI DOM
$25 000 $204 655 $401 845 $887 783 $3 958 084 High KDPI DOM High KDPI DOM High KDPI DOM
$30 000 $239 335 $451 502 $974 170 $4 275 884 High KDPI DOM High KDPI DOM High KDPI DOM
$35 000 $274 014 $501 159 $1 060 557 $4 593 684 High KDPI DOM High KDPI DOM High KDPI DOM
$40 000 $308 694 $550 816 $1 146 944 $4 911 484 High KDPI DOM High KDPI DOM High KDPI DOM
$45 000 $343 373 $600 473 $1 233 331 $5 229 283 High KDPI DOM High KDPI DOM High KDPI DOM
$50 000 $378 053 $650 130 $1 319 717 $5 547 083 High KDPI DOM High KDPI DOM High KDPI DOM
$55 000 $412 732 $699 788 $1 406 104 $5 864 883 High KDPI DOM High KDPI DOM High KDPI DOM
$60 000 $447 411 $749 445 $1 492 491 $6 182 683 High KDPI DOM High KDPI DOM High KDPI DOM
The cost of DAA therapy varies from $5000 to $60 000 and the time to first dHCV+ kidney from 3 mo to 30 mo. The total period of analysis is 36 mo.
Green, cost effective; blue, survival improved but not cost effective; black, survival not improved despite higher cost.
DAA, direct acting antiviral; DOM, dominant strategy with lower cost and improved survival; KDPI, kidney donor profile index.
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acute rejection and had excellent renal function at the time of 
the trial report.
The favorable results of these trials have led to broader 
adoption of similar protocols outside of the clinical trial 
setting. In 2020, members of the Cleveland Clinic-Florida 
transplant program reported their results of dHCV+ trans-
plant across multiple organs (liver, heart, kidney).10,11 In 
their protocol, DAA treatment was delayed until patients 
were viremic and insurance approval was obtained (median 
72 d). The report described transplants in 64 patients 
with a mean waiting time of 23.5 days from consent to 
transplant. While DAA therapy was not complete for all 
patients at the time of reporting, 48 patients achieved SVR 
and only 1 was found to have resistant HCV infection 
requiring an alternative treatment regimen. Three patients 
who underwent kidney transplant from dHCV+ donors 
with very low viral loads did not become viremic and thus 
were not treated. Importantly, 2 patients developed fibros-
ing sclerosing hepatitis after delay in DAA initiation (8 and 
14 wks), both of whom recovered with DAA therapy and 
achieved SVR.
The clinical success of a strategy of dHCV+ kidney trans-
plant combined with DAA treatment has led to significant 
reductions in organ discard nationally. The proportion of 
patients on the kidney waiting list willing to accept a dHCV+ 
organ increased from 3% in 2007 to 14% in 2018.3 As 
expected, acceptance varies by waiting time. Among newly 
listed patients, 22% were willing to accept a dHCV+ organ 
while only 13% of patients with 5 years or more waiting 
time were willing to accepted a viremic organ. This growing 
acceptance of dHCV+ kidney transplants has contributed to 
500% increase in the annual number of these transplant per-
formed between 2007 and 2018. One result of these broader 
acceptance practices is increased competition for organs, 
longer waiting times for a DHCV+ organ, and a reduction 
in the cost savings associated with accepting viremic organs. 
Before the introduction of DAA, 52.3% of all HCV+ kidneys 
were recovered but not transplanted, compared with 16.7% 
of non-HCV+ kidneys. Following the introduction of DAAs, 
discard of HCV+ kidneys decreased to 37.6% from 2104 to 
2017.12 The economic benefits of this practice are contingent 
on reducing the time to transplant as compared with waiting 
for an uninfected organ. Consequently, alternative allocation 
systems may need to be devised to appropriately transplant 
these organs into patients most likely to benefit.
Although waiting time benefit is likely to be reduced over 
time, overall cost of DAA is also likely to diminish. Recent 
studies suggest that “ultra-short” preemptive treatment (imme-
diately before transplant) followed by a 4-day course of treat-
ment can achieve SVR in up to 93% of patients.13 The current 
study examines the intersection of these trends to establish a 
financial justification for broader adoption of these protocols 
in the United States and international contexts. While single 
payer systems have the benefit of lifetime recovery of the cost 
of HCV therapy improving the cost effectiveness of this treat-
ment, from a purely financial standpoint, currently a patient 
who is able to get an uninfected kidney in <12 months and, 
instead, is transplanted with an HCV+ kidney uses additional 
resources. Conversely, any system that reduces waiting by at 
least 11.5 months provides a dominant strategy, as it is both 
cost saving and life extending. Therefore, impact on expected 
waiting time should be considered in determining the optimal 
patient to receive these valuable organs regardless of payment 
system.
Previous analyses of the cost-effectiveness of transplanta-
tion of dHCV+ organs differ from the current study in sev-
eral ways. Kadetz et al assess the cost effectiveness of this 
approach in Canada. This analysis considered the lifetime 
cost-effectiveness of DHCV+ transplant compared with stay-
ing on the waiting list for a year14 and reported an incremen-
tal cost effectiveness ratio of $56 018 per QALY. Unlike the 
current study, the Canadian study did not assess the minimal 
waiting time necessary for cost equivalence/savings for the 
health insurer given the national healthcare system in Canada 
which benefits from long-term cost savings. In addition, they 
assume that 100% of waitlisted patients are on dialysis, while 
this analysis included the benefits for all waitlisted patients, 
including those not on dialysis. Other analyses have likewise 
considered lifetime cost effectiveness analyses rather than 
financial analyses of direct cost of care which is most rel-
evant to health insurers who need to determine if they will 
support the incremental cost of DAAs.15 Finally, no study 
has reported 2 way sensitivity analyses which examines the 
impact of simultaneous changes in the cost of DAAs and the 
wait time reduction resulting achieved by accepting these 
organs. Eckman et al suggest a reduction in time to transplant 
of >3 years, which will likely not be true given wider use of 
organs, while reductions of <0.7 years were not cost effec-
tive. Furthermore, this cost savings assumes patients are on 
dialysis. The authors also did not consider the implications of 
lower cost of DAA therapy.15
This study is limited by a 3-year window to calculate 
cost and benefits. This window was chosen based on the 
availability of accurate Medicare payment data, as kidney 
transplant-specific Medicare benefits expire at 36 months in 
the absence of age older than 65 years or disability. Thus, 
to provide an accurate tradeoff between waitlist cost (both 
on and off dialysis) and posttransplant expenditures, we 
limited the analytic window. We sought to demonstrate the 
economic benefit of this treatment strategy over this brief 
period to assess the short-term implications of dHCV+ on 
total cost of care, which is relevant for payment decisions 
for private health insurers and budgeting for national health 
systems. Second, we assume SVR with a pan-genotypic medi-
cation (glecaprevir/pibrentasvir). Possibly, a small number 
of patients may require additional therapy, although in real-
world experience retreatment is rare, particularly if treat-
ment is started promptly.16 In addition, some patients who 
are transplanted with dHCV+ donors with low viral loads 
may not require treatment, further reducing the cost of these 
protocols. Finally, we did not perform bootstrapping analyses 
to determine significance levels but instead present sensitivity 
analyses around the key variables.
In conclusion, use of dHCV+ kidney transplant in unin-
fected recipients appears to be clinically and financial ben-
eficial in the context of current organ availability and DAA 
cost. As the cost of therapy decreases, the waiting time 
reduction needed to achieve cost savings will also diminish, 
requiring reexamination of this strategy in even in patients 
likely to undergo transplant rapidly with a dHCV− organ. 
Finally, in patients who consent to receive a high-KDPI 
organ, it is not cost-effective to decline transplant with a 
dHCV-uninfected/high KDPI organ to wait for a dHCV+/
lower KDPI organ.
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